BD's EU Iliac Artery Approval: Incremental Growth Amid Pivotal Capital Allocation Wait

What happened

BD announced CE Marking for its iliac artery treatment, enabling commercialization across the European Union as part of its interventional portfolio. This regulatory milestone aligns with BD's strategy to expand its medical device offerings under the 'New BD' framework post-Waters transaction. However, the DeepValue report highlights that near-term stock performance hinges on executing a $2B accelerated share repurchase and $2B debt repayment from recent proceeds, actions yet to be disclosed. Critical risks, such as tariff escalations beyond the $90 million FY25 impact and recurring remediation charges, remain unaddressed by this approval. Thus, while supportive of long-term revenue, the news doesn't alter the immediate focus on capital allocation and cost management.

Implication

This approval may modestly boost BD's interventional revenue but is unlikely to impact FY26 adjusted EPS guidance of $12.35-$12.65. Investors should prioritize monitoring the pending $2B ASR and debt repayment disclosures, which are direct catalysts for per-share metrics and deleveraging. The news fails to mitigate quantified tariff risks or the potential for further cost pressures from evolving policies. Without progress on capital actions, the 'New BD' narrative remains incomplete, and the stock lacks margin of safety at current valuations. Therefore, this development reinforces a wait stance, as it doesn't address key drivers identified in the DeepValue report.

Thesis delta

No material shift in the investment thesis. The CE Marking for the iliac artery treatment is a routine regulatory step that doesn't impact critical factors like capital allocation execution, tariff management, or specified item reduction. The thesis remains unchanged, with a 'WAIT' rating pending confirmation of capital actions and clearer cost headwinds.